The remarkable clinical responses observed in RET fusion-positive lung cancer, RET-mutant MTC, and other RET-driven malignancies highlight the potential of these inhibitors to significantly improve outcomes for patients facing these challenging cancers. This evidence concerns the gene RET and lung cancer.